Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Regen BioPharma Inc files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0.1
0.11
0.1
0.11
0.11
0.06
0.13
0.24
0.24
0.24
Research and development
0.67
1.15
0.37
0.05
0.01
0.04
0.16
0.21
0.15
0.01
General and administrative
1.66
0.82
0.74
0.5
0.25
0.12
0.03
0.04
0.06
0.08
Operating expenses
0.92
0.65
0.58
Operating income
-2.96
-2.51
-1.43
-0.76
-0.21
-0.2
-0.34
-0.69
-0.42
-0.34
Interest expense
0.03
0.1
0.26
0.3
0.33
0.32
0.14
0.06
0.07
0.16
Interest income
0
0
Other non-operating income
2.78
1.84
Pre-tax income
1.16
-0.67
-1.27
Income tax
0
0
Net income to minority interests
0
0
Net income
-7.75
-5.84
-4.72
-2.62
3.41
-6.77
2.44
1.16
-0.67
-1.27
EPS, basic
-0.06
-0.04
-0.03
-0.00
0.00
-0.00
0.71
0.29
-0.16
-0.05
EPS, diluted
-0.06
-0.04
-0.03
-0.00
0.00
-0.00
0.71
0.29
-0.16
-0.05
Shares, basic (weighted)
128
141
152
2,071
1,410
3,012
3.14
3.54
4.11
23.5
Shares, diluted (weighted)
128
141
152
2,071
1,410
3,012
3.14
3.54
4.11
23.5
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
0.02
0.27
0.01
0.01
0
0.73
0.05
0.12
0
0.07
Receivables
0.08
0
0
0.07
0.1
0.21
0.25
0
0.09
0.2
Other current assets
0.07
0.03
0.01
0
0
0.05
0.02
0.01
0.05
0
Total current assets
0.21
0.48
0.04
0.08
0.1
0.99
0.34
0.13
0.14
0.27
Long-term investments
0.02
Total assets
0.32
0.94
0.21
0.1
0.12
1.21
0.56
0.35
0.16
0.27
Accounts payable
0.24
0.5
0.08
0.09
0.11
0.09
0.03
0.03
0.03
0
Accrued liabilities
1.64
1.66
1.84
Deferred revenue
1.47
1.34
Short-term debt
0.11
Total current liabilities
0.8
5.86
8.67
11
7.46
14.7
8.6
5.31
5.38
6.56
Long-term debt
0
0.15
Total liabilities
0.91
6.2
9.33
11
7.46
14.7
8.6
5.46
5.38
6.56
Total debt
0.11
Paid-in capital
19
6.64
7.52
8.26
8.31
8.64
11.6
14.6
15.4
15.6
Retained earnings
-20.2
-12.7
-17.5
-20
-16.6
-23.3
-20.9
-19.7
-20.4
-21.7
Other comprehensive income
-0.08
0.09
0.05
0
-0.2
-0.22
Shareholders' equity
-0.59
-5.25
-9.12
-10.9
-7.33
-13.5
-8.04
-5.1
-5.22
-6.28
Minority interests
0
0
Total equity
-0.59
-5.25
-9.12
-10.9
-7.33
-13.5
-8.04
-5.1
-5.22
-6.28
Total liabilities and equity
0.32
0.94
0.21
0.1
0.12
1.21
0.56
0.35
0.16
0.27
Shares outstanding
140
140
180
600
1,605
4,351
3.35
3.51
5.26
39.4
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-7.75
-5.84
-4.72
-2.62
3.41
-6.77
2.44
1.16
-0.67
-1.27
Stock-based compensation
0.35
0.01
Change in receivables
0.08
-0.08
0
-0.07
-0.03
-0.11
-0.04
0.25
-0.09
-0.11
Change in payables
0.21
0.25
-0.42
0.01
0.02
-0.02
-0.06
0
-0
0
Cash from operations
-1.67
-1.89
-1.58
-0.48
0.02
-1.13
-0.61
-0.17
-0.75
-0.38
Cash from investing
0
-0.01
0.05
0
0.5
0.03
Stock issued
0.56
0.06
Cash from financing
1.66
2.14
1.32
0.43
-0.03
1.36
-0.09
0.24
0.63
0.45
Net change in cash
-0.01
0.25
-0.26
-0
-0.01
0.73
-0.68
0.07
-0.12
0.07
Interest paid
0.01
0.02
0.05
0.02
0
0.03
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $0.00 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-339.8%
Operating income / revenue.
Pre-tax margin
-501.4%
Pre-tax income / revenue.
Net margin
-501.4%
Net income / revenue.
Operating cash flow margin
-188.2%
Cash from operations / revenue.
Return on assets (ROA)
-412.5%
Net income / average total assets.
R&D / revenue
94.7%
Research and development expense / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
0.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
23.5%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
16.5%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
70.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-21.1%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
17.4%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
472.3%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
95.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
-55.9%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
0.05x
Current assets / current liabilities.
Quick ratio
0.05x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.00x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
Operating cash flow per share
-$0.00
Cash from operations / diluted weighted shares.
Book value per share
-$0.01
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
0.71x
Market cap / revenue.
EV/Sales
0.71x
Enterprise value / revenue.
Earnings yield
-708.1%
Net income / market cap (the inverse of P/E).
What was Regen BioPharma Inc's revenue in fiscal 2025?
Regen BioPharma Inc reported revenue of $236.6K for fiscal 2025, 0% higher than the year before.
Was Regen BioPharma Inc profitable in fiscal 2025?
No. It reported a net loss of $1.3M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.